Stock Market News
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) Has a Certified Sales Force Providing National Coverage with Customers for Approximately 80% of Current U.S. Ketamine Sales
Commercial Launch Announcement Marks a New Chapter for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) — FDA-Approved Preservative-Free Ketamine Now Being Sold, 17-Person National Sales Team Activated, Market Relationships Cover Approximately 80% of U.S. Ke
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Also Received an $11 Million Dollar Award for Robotic Magnetic Stimulation with Pharma Treatment for Resistant Depression
A Landmark October 30th FDA Approval, Commercial Manufacturing Readiness, Two-Year Stability Results, and an $11.25 Million DARPA Research Contract Put NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) at an Important Turning Point in Its Growth
$SNNC acquires Majority Stake in New Joint Venture With Doc-Rx Opens the Door to Telehealth, U.S.-Made Peptides and an Ambitious Wellness Clinic Expansion Strategy
$CYCU Boasts a 30 Million Annual Run Rate After Signing Largest Contract Ever, Valued Over $54 Million
Eagle Springs has restarted with a 5,000-barrel-per-day capacity, a proposed $50 million non-dilutive Nevada oil initiative and a substantial Utah resource opportunity, Sky Quarry $SKYQ is advancing its vision of a more integrated Western U.S. energy plat
With relationships spanning 600 telecommunications operators, a potential reach of 2.3 billion end users, and fresh momentum in mobile entertainment, IQSTEL is advancing its strategy to transform a substantial telecommunications platform into a higher-mar
NRXP Reports Three Successfully Manufactured Commercial Lots, Two-Year Stability Data, and Commercially Releasable Supply Pending FDA Approval — While an $11.18 Million DARPA Contract Expands the Company's Research Opportunities
October 15 FDA Update Confirms Minor Labeling Changes Ahead of November 10 Goal Date, While an $11.18 Million DARPA Contract and Innovative Depression Research Expand the Company's Potential
New SmallCapVoice interview with $SKYQ puts the spotlight on a restarted Nevada refinery, 5,000-barrel-per-day potential, a non-dilutive $50 million oil-development initiative and Sky Quarry's plans to ramp both Nevada and Utah operations.
Today's landmark defense contract launches the FDA-approved SPARC-TMS trial while NRx simultaneously advances its preservative-free ketamine program, HOPE Therapeutics and an expanding CNS pipeline
As fentanyl continues to drive an enormous public-health challenge in the United States, Nutriband's AVERSA™ technology is being developed to address a different but important piece of the problem: abuse, misuse, diversion and accidental exposure involvin
Cycurion, Inc. (N A S D A Q: CYCU) Expands From Government Cybersecurity Into Public Safety, Healthcare, AI, Fleet Analytics and Commercial Markets as Q2 Margins Surge Nearly 5X and Management Authorizes $500K Share Repurchases
Today's air-permit approval and immediate Eagle Springs restart mark a major operational milestone, while 5,000-barrel-per-day capacity, 15,000 barrels of crude inventory, Nevada oil-development plans and a tightening Western refining market put Sky Quarr
$NTRB reaches a new 52-week high of $9.00 and closes at $8.99, extending a powerful September advance as the company approaches the September 30 expiration of 910,904 publicly traded warrants and continues advancing its AVERSA™ abuse-deterrent transdermal
Today's Proposed Combination Could Significantly Expand CDIX's Healthcare Footprint — While New Equity, Warrants and Exercise Activity Put the Capital Structure Squarely in Focus
New worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's platform, creating a potential path from patient subtypes and biomarkers to biological mechanisms and therapeutic targets. Positioned for $400M to $1.2 Billion US Coun
With $NTRB shares gaining significant momentum in September, investors are watching a rapidly approaching warrant expiration, new intellectual-property progress for Nutriband's abuse-deterrent fentanyl platform, strengthening visibility through Nasdaq's b
With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts
Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to commercializ